Investigators at University of Washington Describe Findings in Type 2 Diabetes (Impact of Continuous Glucose Monitoring On Emergency Department Visits and All-cause Hospitalization Rates Among Medicaid Beneficiaries With Type 2 Diabetes Treated …): Nutritional and Metabolic Diseases and Conditions – Type 2 Diabetes

2024 DEC 09 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Investigators publish new report on Nutritional and Metabolic Diseases and Conditions - Type 2 Diabetes. According to news reporting originating from Seattle, Washington, by NewsRx correspondents, research stated, “The increasing prevalence of diabetes in the United States continues to drive a steady rise in health care resource utilization, especially emergency department visits and all-cause hospitalizations, and the associated costs. To investigate the impact of continuous glucose monitoring (CGM) on emergency department visits and all-cause hospitalizations among Medicaid beneficiaries with type 2 diabetes (T2D) treated with multiple daily insulin injections (MDIs) or basal insulin therapy (BIT) in a real-world setting.”

Our news editors obtained a quote from the research from the University of Washington, “In this retrospective, 12-month analysis, we used the Inovalon Insights claims dataset to evaluate the effects of CGM acquisition on emergency department visits and all-cause hospitalizations in the Managed Medicaid population. The analysis included 44,941 beneficiaries with T2D who were treated with MDIs (n = 35,367) or BIT (n = 9,574). Primary outcomes were changes in the number of emergency department visits and all-cause hospitalizations following 6 months after acquisition of CGM (post-index period) compared with 6 month prior to CGM acquisition (pre-index period). The first claim for CGM was the index date. Inclusion criteria were as follows: aged younger than 65 years, diagnosis of T2D, claims for short- or rapid-acting insulin (MDI group) or basal insulin (not rapid-acting) (BIT group), acquisition of a CGM device between January 1, 2017, and September 30, 2022, and continuous enrollment in their health plan throughout the pre-index and post-index periods. In the MDI group, all-cause inpatient hospitalization rates decreased from 3.25 to 2.29 events/patient-year (hazard ratio = 0.12; 95% CI = 0.11-0.13; P< 0.001) and emergency department visit rates decreased from 2.15 to 1.86 events/patient-year (hazard ratio = 0.52; 95% CI = 0.50-0.53; P< 0.001). In the BIT group, all-cause inpatient hospitalization rates decreased from 1.63 to 1.39 events/patient-year (hazard ratio = 0.11; 95% CI = 0.09-0.12; P< 0.001) and emergency department visit rates decreased from 1.60 to 1.43 events/patient-year (hazard ratio = 0.47; 95% CI = 0.44-0.50; P< 0.001).”

According to the news editors, the research concluded: “Acquisition of CGM is associated with significant reductions in emergency department visits and all-cause hospitalizations among people with T2D treated with MDIs or BIT.”

This research has been peer-reviewed.

For more information on this research see: Impact of Continuous Glucose Monitoring On Emergency Department Visits and All-cause Hospitalization Rates Among Medicaid Beneficiaries With Type 2 Diabetes Treated With Multiple Daily Insulin or Basal Insulin Therapy. Journal of Managed Care & Specialty Pharmacy, 2024;30(10). Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

The news editors report that additional information may be obtained by contacting Irl B. Hirsch, University of Washington, School of Medicine, Seattle, WA 98195, United States. Additional authors for this research include Bhavya Sree Burugapalli, Laura Brandner, Yeesha Poon, Marie Frazzitta, Lakshmi Godavarthi and Naunihal Virdi.

(Our reports deliver fact-based news of research and discoveries from around the world.)